Neuronetics, Inc. (STIM) stock
STIMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.28+0.03 (+2.40%)
Close on Nov 17, 2026Market cap $97.53MP/E –Yield –
Neuronetics r&d expenses
Research and development expenses are spending on new products and technology.
Neuronetics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.87M, down 49.4% year over year. For fiscal 2025 it was $6.58M, down 48.4% from the year before. The highest annual figure on record is $13.75M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.58M | -48.4% |
| FY2024 | Dec 31, 2024 | $12.77M | +34.2% |
| FY2023 | Dec 31, 2023 | $9.52M | +1.9% |
| FY2022 | Dec 31, 2022 | $9.34M | +17.8% |
| FY2021 | Dec 31, 2021 | $7.92M | -13.9% |
| FY2020 | Dec 31, 2020 | $9.20M | -33.1% |
| FY2019 | Dec 31, 2019 | $13.75M | +67.0% |
| FY2018 | Dec 31, 2018 | $8.23M | +3.7% |
| FY2017 | Dec 31, 2017 | $7.94M | -3.5% |
| FY2016 | Dec 31, 2016 | $8.22M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.34M | -25.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.36M | -15.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.67M | -71.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.50M | -37.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.80M | -19.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.62M | -31.2% |
| Q4 FY2024 | Dec 31, 2024 | $5.77M | +161.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.42M | +12.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.24M | -5.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.35M | -15.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.21M | -29.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.16M | -8.2% |
| Q2 FY2023 | Jun 30, 2023 | $2.36M | +15.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.79M | +54.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.14M | +80.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.35M | +49.1% |
| Q2 FY2022 | Jun 30, 2022 | $2.05M | -10.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.80M | -22.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.74M | -17.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.58M | -19.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.29M | +8.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.31M | -23.5% |
| Q4 FY2020 | Dec 31, 2020 | $2.11M | -50.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.95M | -44.1% |
| Q2 FY2020 | Jun 30, 2020 | $2.12M | -34.4% |
| Q1 FY2020 | Mar 31, 2020 | $3.02M | +8.4% |
| Q4 FY2019 | Dec 31, 2019 | $4.25M | +91.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.49M | +64.2% |
| Q2 FY2019 | Jun 30, 2019 | $3.22M | +38.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.79M | +79.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.22M | +15.8% |
| Q3 FY2018 | Sep 30, 2018 | $2.13M | +15.3% |
| Q2 FY2018 | Jun 30, 2018 | $2.33M | +8.5% |
| Q1 FY2018 | Mar 31, 2018 | $1.56M | -23.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.92M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.84M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.15M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.03M | – |
See a number that looks wrong?